TriVascular Inc. says it reeled in a $40 million Series E round for its Ovation line of stent grafts for treating abdominal aortic aneurysms. TriVascular Inc. said it's added another $40 million to its coffers in a Series E round it plans to use to expand its commercial footprint and " to fuel product pipeline and clinical research activities." Santa Rosa, Calif.-based TriVascular makes the Ovation line of stent grafts for treating abdominal aortic aneurysms.
Help employers find you! Check out all the jobs and post your resume.
